MLEC vs MLTX

Moolec Science SA vs MoonLake Immunotherapeutics — Valuation Comparison 2026

MLEC

Biotechnology
Moolec Science SA
Quality
1.7
out of 10
Value Trap
Price
$7.20
Last close
Models
6/13
Active
VS

MLTX

Biotechnology
MoonLake Immunotherapeutics
Quality
4.0
out of 10
Value Trap
30
LOW
Price
$18.68
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType MLEC Fair ValueMLEC Upside MLTX Fair ValueMLTX Upside
Bayesian DCF Intrinsic $1.91 -73.5% $6.65 -64.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $5.37 -25.4% $0.45 -97.3%
Dynamic NAV Asset-Based $0.35 -95.2% $4.61 -75.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for MLEC vs MLTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MLEC vs MLTX — Which Stock Is More Undervalued?

MLTX scores higher with a 4.0/10 quality rating vs MLEC's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Moolec Science SA (MLEC) and MoonLake Immunotherapeutics (MLTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MLEC currently trades at $7.20 with a QOC of 1.7/10, while MLTX trades at $18.68 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).